New York:
American pharmaceutical company Pfizer has said it will allow its experimental antiviral Covid 19 drug to be manufactured in 95 poor and middle-class countries. Pfizer will sell the tablets under the Pixlweed brand name. The risk of hospitalization or death in adults affected by the drug code was found to be 89% effective.
According to a statement from the company, the countries will be able to develop the drug under a licensing agreement with the International Public Health Group Medicine Patient Pool (MPP). The group will issue sub-licenses to qualified pharmaceutical companies so that they can manufacture PF 07321332 on their own.
The drug will use an HIV drug called Retonavir, which is already widely available. A similar agreement was reached.
The agreements between the two companies are exceptional, reflecting the importance of the need to provide effective treatment at low cost with respect to CODE. Congratulations on the addition of another weapon. He said a generic version of Pfizer is expected to be available in the next few months.
Pfizer and the MPP said the 95 countries covered by the agreement cover 53 percent of the world’s population, including poor, low-income middle and some high-income middle-class countries. “We need to make sure that people have access to breakthrough treatments no matter what the circumstances,” said Executive Albert Borla.
Pfizer will not charge royalties on the sale of the drug to low-income countries, and the facility will be available to other countries in the treaty until Code 19 is declared a Public Health Emergency by the World Health Organization. ۔
Pfizer’s demand for the drug is high, and according to the company, it expects to produce 180,000 courses by the end of December 2021, and at least 50 million courses by the end of 2022. The cost of a drug course from each country will be based on its income, in the United States it will cost close to 700 700.
